• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.

作者信息

Aihara Tomohiko, Toyama Tatsuya, Takahashi Masato, Yamamoto Yutaka, Hara Fumikata, Akabane Hiromitsu, Fujisawa Tomomi, Ishikawa Takashi, Nagai Shigenori, Nakamura Rikiya, Tsurutani Junji, Ito Yoshinori, Mukai Hirofumi

机构信息

Breast Center, Aihara Hospital, 3-4-30, Makiochi, Minoh, Osaka, 562-0004, Japan.

Department of Breast and Endocrine Surgery, Nagoya City University Hospital, Nagoya, Japan.

出版信息

Breast Cancer. 2016 May;23(3):329-42. doi: 10.1007/s12282-016-0670-y. Epub 2016 Feb 24.

DOI:10.1007/s12282-016-0670-y
PMID:26910609
Abstract
摘要

相似文献

1
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.日本乳腺癌学会《乳腺癌全身治疗临床实践指南》，2015年版。
Breast Cancer. 2016 May;23(3):329-42. doi: 10.1007/s12282-016-0670-y. Epub 2016 Feb 24.
2
Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.内分泌反应性和HER2/neu过表达在多模式术前治疗的炎性乳腺癌中的作用。
Breast J. 2008 Sep-Oct;14(5):435-41. doi: 10.1111/j.1524-4741.2008.00619.x.
3
Breast cancer in women under 40.40岁以下女性的乳腺癌
Oncology (Williston Park). 2009 May;23(6):465-74.
4
Breast cancer in young women: clinical decision-making in the face of uncertainty.年轻女性乳腺癌：面对不确定性时的临床决策
Oncology (Williston Park). 2009 May;23(6):474, 477.
5
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.乳腺癌管理的多学科方法，第2部分：治疗考量
Mayo Clin Proc. 2007 Sep;82(9):1131-40. doi: 10.4065/82.9.1131.
6
Breast intervention and breast cancer treatment options.乳房干预措施及乳腺癌治疗方案。
Radiol Technol. 2015 May-Jun;86(5):535M-558M; quiz 559-62.
7
[Strategies of breast cancer treatment based on determination of biological subtype].基于生物学亚型判定的乳腺癌治疗策略
Vopr Onkol. 2011;57(5):542-52.
8
Effect of CYP2D6 polymorphisms on breast cancer recurrence.CYP2D6 多态性对乳腺癌复发的影响。
Cancer. 2012 Mar 1;118(5):1221-7. doi: 10.1002/cncr.26407. Epub 2011 Aug 5.
9
The ethics of CYP2D6 testing for patients considering tamoxifen.考虑使用他莫昔芬的患者进行CYP2D6检测的伦理学问题。
Breast Cancer Res. 2007;9(2):103. doi: 10.1186/bcr1663.
10
Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.他莫昔芬对激素受体阳性乳腺癌女性的益处及CYP2D6检测
Clin J Oncol Nurs. 2013 Apr;17(2):174-9. doi: 10.1188/13.CJON.174-179.

引用本文的文献

1
Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry.免疫检查点抑制剂时代之前可手术三阴性乳腺癌新辅助化疗与辅助化疗的比较：一项来自日本国家临床数据库-乳腺癌登记处的回顾性研究
Breast. 2025 Jun;81:104460. doi: 10.1016/j.breast.2025.104460. Epub 2025 Mar 25.
2
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).帕妥珠单抗治疗人表皮生长因子受体 2 阳性晚期乳腺癌的随机、开放标签 III 期研究（PRECIOUS）。
Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23.
3
A Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment.
一项关于接受雷洛昔芬治疗的韩国骨质疏松症女性乳腺癌发病率的全国性研究。
J Breast Cancer. 2021 Jun;24(3):280-288. doi: 10.4048/jbc.2021.24.e28. Epub 2021 May 14.
4
A Case of Pure Mucinous Breast Carcinoma in a 25-Year-Old Female Who Showed Complete Pathological Response to Neoadjuvant Chemotherapy despite Poor Clinical Response.一名25岁女性的纯黏液性乳腺癌病例，该患者尽管临床反应不佳，但对新辅助化疗显示出完全病理缓解。
Breast Care (Basel). 2020 Oct;15(5):538-542. doi: 10.1159/000504125. Epub 2019 Dec 12.
5
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.曲妥珠单抗-德鲁替康在人表皮生长因子受体 2 阳性乳腺癌和其他实体瘤患者中的群体药代动力学。
Clin Pharmacol Ther. 2021 May;109(5):1314-1325. doi: 10.1002/cpt.2096. Epub 2020 Dec 6.
6
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.多组学分析鉴定 HSD17B4 甲基化沉默是 HER2 阳性乳腺癌对 HER2 靶向治疗的预测和反应标志物。
Sci Rep. 2020 Sep 23;10(1):15530. doi: 10.1038/s41598-020-72661-9.
7
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.帕妥珠单抗联合曲妥珠单抗和多西他赛作为一线治疗用于不可切除或复发性人表皮生长因子受体 2（HER2）阳性乳腺癌的日本患者的疗效和安全性：COMACHI 研究。
Breast Cancer Res Treat. 2021 Jan;185(1):125-134. doi: 10.1007/s10549-020-05921-x. Epub 2020 Sep 13.
8
Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.避免和缩短 I 期和 II 期三阴性乳腺癌的新辅助化疗：Ki-67 标记指数的重要性和对大汗腺型病变的认识。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820943246. doi: 10.1177/1533033820943246.
9
Radiogenomics of magnetic resonance imaging and a new multi-gene classifier for predicting recurrence prognosis in estrogen receptor-positive breast cancer: A preliminary study.磁共振成像的放射基因组学及一种用于预测雌激素受体阳性乳腺癌复发预后的新型多基因分类器：一项初步研究。
Medicine (Baltimore). 2020 Apr;99(16):e19664. doi: 10.1097/MD.0000000000019664.
10
Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.绝经前乳腺癌患者接受他莫昔芬治疗时，化疗后卵泡重新生长与卵巢过度刺激密切相关：一项多中心回顾性队列研究。
BMC Cancer. 2020 Jan 29;20(1):67. doi: 10.1186/s12885-020-6549-5.